Business
OncBioMune Reports Record Monthly Sales for Bekunis(R) in May
OncBioMune Reports Record Monthly Sales for Bekunis(R) in May.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Reports Record Monthly Sales for Bekunis(R) in May\n\nOncBioMune Reports Record Monthly Sales for Bekunis(R) in May\n\nBATON ROUGE, LA--(Marketwired - May 31, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology, today reports that May sales in Mexico of its licensed over-the-counter product Bekunis® for constipation reached a record monthly total of approximately US$96,000. As disclosed on March 27, 2017, sales for the first six months since the launch of Bekunis® and Cirkused® (for stress) in Mexico totaled approximately US$330,000, with Bekunis® representing the lion's share of sales. With the strong month of May for Bekunis® alone, OncBioMune is confident that it will meet or exceed its 2017 sales goal for the products in the range of US$750,000 to US$850,000. With the leading competition to Bekunis® recently exiting the market at a time when brand recognition of OncBioMune's product is quickly growing, management anticipates continued acceleration in sales. In order to facilitate greater market penetration, OncBioMune is interviewing industry veterans with the intention of adding a new Product Manager to the staff in June with the primary directive of creating an even higher impact on direct marketing and adding addition drugstores to the sales channel.\"The launch of Bekunis® has certainly been successful, with positive feedback on our marketing that is translating to sales that have regularly exceeded our expectations,\" commented Manuel Cosme Odabachian, OncBioMune's General Manager of Global Operations. \"We are relentless in our pursuit of bringing more products to market in Mexico, efforts that paid off with the approval from the Mexican Ministry of Health this week for our licensed male fertility product Andfrt® that we believe should add at least US$500,000 in sales during its first full year on the market following launch next quarter. Additionally, we have several other products under dossier elaboration for commercialization later this year and ongoing negotiations with international pharmaceutical companies to bring high-revenue prescription drugs to fill areas of unmet need in Mexico.\"S...